Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest

Kristen Massimino, Crystal J. Hessman, Michelle C. Ellis, Arpana Naik, John Vetto

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND: Recent clinical trials have suggested no survival benefit for completion axillary node dissection (CALND) after sentinel lymph node biopsy (American College of Surgeons Oncology Group Z0011) and no clinically meaningful benefit for the routine use of immunohistochemistry (National Surgical Adjuvant Breast and Bowel Project B-32) in clinically node-negative breast cancer. METHODS: A 12-question electronic survey was distributed to members of 3 Pacific Northwest surgical societies. Surgeons were queried regarding the impact of the trial results on their surgical management of breast cancer. RESULTS: The 181 respondents reported performing fewer CALNDs (63%), fewer intraoperative frozen sections (21%), and no immunohistochemistry (12%) because of trial data. However, 28% of surgeons continued to perform CALND in patients with 1 to 2 positive sentinel lymph nodes undergoing lumpectomy and postoperative radiation. CONCLUSIONS: Recent trial data have impacted the performance of CALNDs and the pathological evaluation of sentinel lymph nodes among Pacific Northwest surgeons. Our results suggest a need for regional surgical societies to disseminate practice-changing trial data to members.

Original languageEnglish (US)
Pages (from-to)618-622
Number of pages5
JournalAmerican Journal of Surgery
Volume203
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Northwestern United States
Breast
Dissection
Immunohistochemistry
Breast Neoplasms
Sentinel Lymph Node Biopsy
compound A 12
Segmental Mastectomy
Frozen Sections
Clinical Trials
Radiation
Survival
Surgeons
Surveys and Questionnaires
Sentinel Lymph Node

Keywords

  • American College of Surgeons Oncology Group Z0011
  • Completion axillary dissection
  • Immunohistochemistry
  • National Surgical Adjuvant Breast and Bowel Project B-32
  • survey

ASJC Scopus subject areas

  • Surgery

Cite this

Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest. / Massimino, Kristen; Hessman, Crystal J.; Ellis, Michelle C.; Naik, Arpana; Vetto, John.

In: American Journal of Surgery, Vol. 203, No. 5, 05.2012, p. 618-622.

Research output: Contribution to journalArticle

@article{1291636540bd452b9381945cb4577582,
title = "Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest",
abstract = "BACKGROUND: Recent clinical trials have suggested no survival benefit for completion axillary node dissection (CALND) after sentinel lymph node biopsy (American College of Surgeons Oncology Group Z0011) and no clinically meaningful benefit for the routine use of immunohistochemistry (National Surgical Adjuvant Breast and Bowel Project B-32) in clinically node-negative breast cancer. METHODS: A 12-question electronic survey was distributed to members of 3 Pacific Northwest surgical societies. Surgeons were queried regarding the impact of the trial results on their surgical management of breast cancer. RESULTS: The 181 respondents reported performing fewer CALNDs (63{\%}), fewer intraoperative frozen sections (21{\%}), and no immunohistochemistry (12{\%}) because of trial data. However, 28{\%} of surgeons continued to perform CALND in patients with 1 to 2 positive sentinel lymph nodes undergoing lumpectomy and postoperative radiation. CONCLUSIONS: Recent trial data have impacted the performance of CALNDs and the pathological evaluation of sentinel lymph nodes among Pacific Northwest surgeons. Our results suggest a need for regional surgical societies to disseminate practice-changing trial data to members.",
keywords = "American College of Surgeons Oncology Group Z0011, Completion axillary dissection, Immunohistochemistry, National Surgical Adjuvant Breast and Bowel Project B-32, survey",
author = "Kristen Massimino and Hessman, {Crystal J.} and Ellis, {Michelle C.} and Arpana Naik and John Vetto",
year = "2012",
month = "5",
doi = "10.1016/j.amjsurg.2011.12.015",
language = "English (US)",
volume = "203",
pages = "618--622",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest

AU - Massimino, Kristen

AU - Hessman, Crystal J.

AU - Ellis, Michelle C.

AU - Naik, Arpana

AU - Vetto, John

PY - 2012/5

Y1 - 2012/5

N2 - BACKGROUND: Recent clinical trials have suggested no survival benefit for completion axillary node dissection (CALND) after sentinel lymph node biopsy (American College of Surgeons Oncology Group Z0011) and no clinically meaningful benefit for the routine use of immunohistochemistry (National Surgical Adjuvant Breast and Bowel Project B-32) in clinically node-negative breast cancer. METHODS: A 12-question electronic survey was distributed to members of 3 Pacific Northwest surgical societies. Surgeons were queried regarding the impact of the trial results on their surgical management of breast cancer. RESULTS: The 181 respondents reported performing fewer CALNDs (63%), fewer intraoperative frozen sections (21%), and no immunohistochemistry (12%) because of trial data. However, 28% of surgeons continued to perform CALND in patients with 1 to 2 positive sentinel lymph nodes undergoing lumpectomy and postoperative radiation. CONCLUSIONS: Recent trial data have impacted the performance of CALNDs and the pathological evaluation of sentinel lymph nodes among Pacific Northwest surgeons. Our results suggest a need for regional surgical societies to disseminate practice-changing trial data to members.

AB - BACKGROUND: Recent clinical trials have suggested no survival benefit for completion axillary node dissection (CALND) after sentinel lymph node biopsy (American College of Surgeons Oncology Group Z0011) and no clinically meaningful benefit for the routine use of immunohistochemistry (National Surgical Adjuvant Breast and Bowel Project B-32) in clinically node-negative breast cancer. METHODS: A 12-question electronic survey was distributed to members of 3 Pacific Northwest surgical societies. Surgeons were queried regarding the impact of the trial results on their surgical management of breast cancer. RESULTS: The 181 respondents reported performing fewer CALNDs (63%), fewer intraoperative frozen sections (21%), and no immunohistochemistry (12%) because of trial data. However, 28% of surgeons continued to perform CALND in patients with 1 to 2 positive sentinel lymph nodes undergoing lumpectomy and postoperative radiation. CONCLUSIONS: Recent trial data have impacted the performance of CALNDs and the pathological evaluation of sentinel lymph nodes among Pacific Northwest surgeons. Our results suggest a need for regional surgical societies to disseminate practice-changing trial data to members.

KW - American College of Surgeons Oncology Group Z0011

KW - Completion axillary dissection

KW - Immunohistochemistry

KW - National Surgical Adjuvant Breast and Bowel Project B-32

KW - survey

UR - http://www.scopus.com/inward/record.url?scp=84859915758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859915758&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2011.12.015

DO - 10.1016/j.amjsurg.2011.12.015

M3 - Article

C2 - 22445745

AN - SCOPUS:84859915758

VL - 203

SP - 618

EP - 622

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5

ER -